Header Logo

Connection

ROBERT ATMAR to Influenza, Human

Back to Details
This is a "connection" page, showing publications ROBERT ATMAR has written about Influenza, Human.
ROBERT ATMAR
Connection Strength
5.724
Influenza, Human
  1. Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial. Vaccine. 2023 04 17; 41(16):2716-2722.
    View in: PubMed
    Score: 0.530
  2. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season. MMWR Recomm Rep. 2020 08 21; 69(8):1-24.
    View in: PubMed
    Score: 0.443
  3. Improving Influenza Prevention: Modest Changes With Large Effects. Clin Infect Dis. 2020 06 10; 70(12):2503-2504.
    View in: PubMed
    Score: 0.437
  4. Searching for Improved Flu Vaccines-The Time Is Now. J Infect Dis. 2020 01 01; 221(1):1-4.
    View in: PubMed
    Score: 0.424
  5. Influenza Vaccines After 7 Decades: Still on the Learning Curve. J Infect Dis. 2019 09 13; 220(8):1240-1242.
    View in: PubMed
    Score: 0.415
  6. Influenza Vaccination of Patients Receiving Statins: Where Do We Go From Here? J Infect Dis. 2016 Apr 15; 213(8):1211-3.
    View in: PubMed
    Score: 0.317
  7. Intanza(?): a new intradermal vaccine for seasonal influenza. Expert Rev Vaccines. 2010 Dec; 9(12):1399-409.
    View in: PubMed
    Score: 0.226
  8. Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol. 2009; 333:323-44.
    View in: PubMed
    Score: 0.198
  9. Preparing for a possible pandemic: influenza A/H5N1 vaccine development. Curr Opin Pharmacol. 2007 Oct; 7(5):484-90.
    View in: PubMed
    Score: 0.179
  10. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006 Nov 01; 43(9):1135-42.
    View in: PubMed
    Score: 0.169
  11. Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59?. Vaccine. 2025 Feb 15; 47:126702.
    View in: PubMed
    Score: 0.150
  12. Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens. Vaccine. 2025 Feb 15; 47:126689.
    View in: PubMed
    Score: 0.150
  13. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 06 14; 78(6):1757-1768.
    View in: PubMed
    Score: 0.144
  14. A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy Adults. J Infect Dis. 2023 08 11; 228(3):287-298.
    View in: PubMed
    Score: 0.136
  15. Topical Imiquimod Does Not Provide an Adjuvant Effect When Administered With Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults. J Infect Dis. 2021 11 22; 224(10):1712-1719.
    View in: PubMed
    Score: 0.121
  16. Influenza Challenge Models: Ready for Prime Time? Clin Infect Dis. 2020 12 31; 71(11):3012-3013.
    View in: PubMed
    Score: 0.114
  17. An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine. Hum Vaccin Immunother. 2020 12 01; 16(12):3138-3145.
    View in: PubMed
    Score: 0.109
  18. Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents. Vaccine. 2019 08 23; 37(36):5161-5170.
    View in: PubMed
    Score: 0.103
  19. Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis. Vaccine. 2019 09 03; 37(37):5535-5543.
    View in: PubMed
    Score: 0.102
  20. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019 05 01; 37(19):2561-2568.
    View in: PubMed
    Score: 0.101
  21. Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. Vaccine. 2016 Jan 20; 34(4):547-554.
    View in: PubMed
    Score: 0.080
  22. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015 Jul 21; 314(3):237-46.
    View in: PubMed
    Score: 0.078
  23. Host Transcriptional Response to Influenza and Other Acute Respiratory Viral Infections--A Prospective Cohort Study. PLoS Pathog. 2015 Jun; 11(6):e1004869.
    View in: PubMed
    Score: 0.077
  24. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 2015 Jan 01; 33(1):163-73.
    View in: PubMed
    Score: 0.074
  25. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis. 2013 Mar 15; 207(6):974-81.
    View in: PubMed
    Score: 0.065
  26. Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans. PLoS One. 2012; 7(12):e50830.
    View in: PubMed
    Score: 0.065
  27. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 01; 206(7):1069-77.
    View in: PubMed
    Score: 0.064
  28. Prior infections with seasonal influenza A/H1N1 virus reduced the illness severity and epidemic intensity of pandemic H1N1 influenza in healthy adults. Clin Infect Dis. 2012 Feb 01; 54(3):311-7.
    View in: PubMed
    Score: 0.060
  29. Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine. 2011 Oct 19; 29(45):8066-72.
    View in: PubMed
    Score: 0.059
  30. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine. 2010 Feb 25; 28(9):2076-9.
    View in: PubMed
    Score: 0.053
  31. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine. 2010 Apr 09; 28(17):3025-9.
    View in: PubMed
    Score: 0.053
  32. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine. 2009 Aug 13; 27(37):5091-5.
    View in: PubMed
    Score: 0.051
  33. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med. 2006 May 22; 166(10):1121-7.
    View in: PubMed
    Score: 0.041
  34. Influenza vaccine in patients with asthma. Expert Rev Vaccines. 2006 Feb; 5(1):111-8.
    View in: PubMed
    Score: 0.040
  35. Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect. 2005 May; 50(4):322-30.
    View in: PubMed
    Score: 0.038
  36. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. J Allergy Clin Immunol. 2004 Apr; 113(4):717-24.
    View in: PubMed
    Score: 0.036
  37. Epidemiology and molecular characterization of co-circulating influenza A/H3N2 virus variants in children: Houston, Texas, 1997-8. Epidemiol Infect. 2003 Jun; 130(3):521-31.
    View in: PubMed
    Score: 0.034
  38. Practical and sensitive screening strategy for detection of influenza virus. J Clin Microbiol. 2002 Nov; 40(11):4353-6.
    View in: PubMed
    Score: 0.032
  39. Comparison of a new neuraminidase detection assay with an enzyme immunoassay, immunofluorescence, and culture for rapid detection of influenza A and B viruses in nasal wash specimens. J Clin Microbiol. 2000 Mar; 38(3):1161-5.
    View in: PubMed
    Score: 0.027
  40. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999 Oct 28; 341(18):1336-43.
    View in: PubMed
    Score: 0.026
  41. Influenza A virus outbreak in a neonatal intensive care unit. Pediatr Infect Dis J. 1999 Sep; 18(9):811-5.
    View in: PubMed
    Score: 0.026
  42. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis. 1998 Jun; 26(6):1418-24.
    View in: PubMed
    Score: 0.024
  43. Typing and subtyping clinical isolates of influenza virus using reverse transcription-polymerase chain reaction. Clin Diagn Virol. 1996 Nov; 7(2):77-84.
    View in: PubMed
    Score: 0.021
  44. Safety and pharmacokinetics of rimantadine small-particle aerosol. Antimicrob Agents Chemother. 1990 Nov; 34(11):2228-33.
    View in: PubMed
    Score: 0.014
  45. Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine. 2009 Aug 27; 27(39):5344-8.
    View in: PubMed
    Score: 0.013
  46. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000 Jan 26; 283(4):499-505.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.